333 related articles for article (PubMed ID: 25040077)
21. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
[TBL] [Abstract][Full Text] [Related]
22. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.
Van Den Neste E; Robin V; Francart J; Hagemeijer A; Stul M; Vandenberghe P; Delannoy A; Sonet A; Deneys V; Costantini S; Ferrant A; Robert A; Michaux L
Leukemia; 2007 Aug; 21(8):1715-22. PubMed ID: 17541398
[TBL] [Abstract][Full Text] [Related]
23. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
[TBL] [Abstract][Full Text] [Related]
24. What do we do with chronic lymphocytic leukemia with 17p deletion?
Sellner L; Denzinger S; Dietrich S; Glimm H; Merkel O; Dreger P; Zenz T
Curr Hematol Malig Rep; 2013 Mar; 8(1):81-90. PubMed ID: 23188619
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
26. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
27. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
28. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
López C; Baumann T; Costa D; López-Guerra M; Navarro A; Gómez C; Arias A; Muñoz C; Rozman M; Villamor N; Colomer D; Montserrat E; Campo E; Carrió A
Br J Haematol; 2012 Mar; 156(5):612-8. PubMed ID: 22150335
[TBL] [Abstract][Full Text] [Related]
29. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
Doneda L; Montillo M; Intropido L; Tedeschi A; Morra E; Larizza L
Cancer Genet Cytogenet; 2003 Jan; 140(1):31-6. PubMed ID: 12550755
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
31. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Edelmann J; Gribben JG
J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
[TBL] [Abstract][Full Text] [Related]
32. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Mikudina B; Goodall M; Adler AI
Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
[No Abstract] [Full Text] [Related]
33. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
34. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.
Forconi F; Rinaldi A; Kwee I; Sozzi E; Raspadori D; Rancoita PM; Scandurra M; Rossi D; Deambrogi C; Capello D; Zucca E; Marconi D; Bomben R; Gattei V; Lauria F; Gaidano G; Bertoni F
Br J Haematol; 2008 Nov; 143(4):532-6. PubMed ID: 18752589
[TBL] [Abstract][Full Text] [Related]
36. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
37. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
[TBL] [Abstract][Full Text] [Related]
38. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
Chin-Yee B; Sadikovic B; Chin-Yee IH
Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
[TBL] [Abstract][Full Text] [Related]
39. The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
Lin K; Lane B; Carter A; Johnson GG; Onwuazor O; Oates M; Zenz T; Stilgenbauer S; Atherton M; Douglas A; Ebrahimi B; Sherrington PD; Pettitt AR
Br J Haematol; 2013 Jan; 160(1):53-62. PubMed ID: 23110309
[TBL] [Abstract][Full Text] [Related]
40. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
